App-Quantinova.ai

Real-world associations between bone-targeted agents and palliative bone radiotherapy in prostate cancer decedents A province-wide population study.

William James Phillips - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Docetaxel

Time trends of overall survival and other outcomes in patients with mHSPC An observational study of U.S. EHR data (TIMES).

Neal D. Shore - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Metastatic castration-resistant prostate cancer

Docetaxel

DASL-HiCaP Darolutamide augments standard therapy for localized very high-risk cancer of the prostate (ANZUP1801)—A randomized phase 3, double-blind, placebo-controlled trial of adding darolutamide to androgen deprivation therapy and definitive or salvage radiation.

Tamim Niazi - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Solid malignancies

Docetaxel

Defining more precisely the effects of docetaxel plus ADT for men with mHSPC Meta-analysis of individual participant data from randomized trials.

Claire Louise Vale - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Docetaxel

Combining IL-12 immunocytokine (M9241) with docetaxel in metastatic prostate cancer A phase I study.

Mohammad O. Atiq - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Docetaxel

PSMA PET findings in patients with undetectable PSA more than 3 years after docetaxel for metastatic castration-sensitive prostate cancer (mCSPC).

Mohammad O. Atiq - American Society of Clinical Oncology Genitourinary (ASCO GU) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Docetaxel

Cutaneous Angiosarcoma of the Phalanx resembling a Pyogenic Granuloma: Case Report

Nohemi Trejo Chavira - American Academy of Dermatology (AAD) , 2022

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Angiosarcoma

Docetaxel

A CASE OF MEMBRANOUS NEPHROPATHY THAT DEVELOPPED AFTER USE OF NIVOLUMAB

K. WAKABAYASHI - International Society of Nephrology (ISN) , 2019

Therapeutic Area

Disease

Drug/Treatment

Endocrine/metabolic Diseases (ME)

Non Small Cell Lung cancer

Docetaxel

Vascular Events Associated With Cisplatin Based Combination Therapy An Analysis From Faers Database

Chitsimann Mann - American Heart Association (AHA) , 2022

Therapeutic Area

Disease

Drug/Treatment

N/A

Docetaxel

A RARE CASE OF CHEMOTHERAPY-INDUCED TAKOTSUBO'S CARDIOMYOPATHY COMPLICATED BY LVOT OBSTRUCTION WITH EVIDENCE OF BROCKENBROUGH-BRAUNWALD MORROW'S SIGN

Adhiraj Bhattacharya - American College of Cardiology (ACC) , 2021

Therapeutic Area

Disease

Drug/Treatment

Pulmonary/Respiratory Diseases

Left ventricular outflow tract obstruction

Docetaxel

Overall Survival in Patients with Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) Treated with Enzalutamide + Androgen Deprivation Therapy by High or Low Disease Volume and Progression to mHSPC (M0 at diagnosis) or De Novo mHSPC (M1 at Diagnosis): Post Hoc Analysis of the Phase 3 ARCHES Trial

Andrew J. Armstrong - New England Section of the American Urological Association (NEAUA) , 2022

Therapeutic Area

Disease

Drug/Treatment

Urology

Prostate cancer

Docetaxel

Neo-AEGIS (Neoadjuvant Trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Final primary outcome analysis.

John V. Reynolds - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Docetaxel

Short-term safety of adjuvant nivolumab therapy after neoadjuvant docetaxel plus cisplatin and 5-FU therapy for locally advanced esophageal squamous cell carcinoma.

Toshiharu Hirose - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Docetaxel

Docetaxel-based triplet neoadjuvant therapy for esophageal adenocarcinoma: A comprehensive analysis of outcomes spanning over a decade.

James Tankel - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal Cancer

Docetaxel

The new prognostic index of advanced gastric cancer using the data from JCOG1013.

Daisuke Takahari - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Docetaxel

A phase II study of preoperative chemotherapy with docetaxel, oxaliplatin, and S-1 followed by gastrectomy with D2 plus para-aortic nodal dissection for gastric cancer with extensive lymph node metastasis: JCOG1704.

Takaki Yoshikawa - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Docetaxel

Post-recurrent survival of a phase III trial comparing adjuvant chemotherapy with docetaxel plus S-1 versus S-1 alone in stage III gastric cancer: A post-hoc analysis of the START-2 trial (JACCRO GC-07).

Hiroo Ishida - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastric Cancer

Docetaxel

Safety and short-term efficacy of neoadjuvant FLOT therapy in patients with resectable esophageal squamous cell carcinoma.

Yuri Yoshinami - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Esophageal squamous carcinoma cell

Docetaxel

A phase 2 study of durvalumab plus DOS (docetaxel, oxaliplatin, S-1) neoadjuvant chemotherapy followed by surgery and adjuvant durvalumab plus S-1 chemotherapy in patients with resectable locally advanced gastric cancer: An interim efficacy report.

Hyung-Don Kim - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Gastroesophageal junction (GEJ) adenocarcinoma

Docetaxel

DNA mismatch repair deficiency and outcomes of patients with resectable locally advanced gastric cancer treated with preoperative docetaxel, oxaliplatin, and S-1 plus surgery and postoperative S-1 or surgery and postoperative S-1: A sub-analysis of the phase 3 PRODIGY trial.

Jaewon Hyung - American Society of Clinical Oncology Gastrointestinal (ASCO GI) , 2023

Therapeutic Area

Disease

Drug/Treatment

Oncology (ONC)

Mismatch repair deficiency

Docetaxel

Filters

2459 Abstracts